174 related articles for article (PubMed ID: 31870179)
1. Aberrantly Expressed Timeless Regulates Cell Proliferation and Cisplatin Efficacy in Cervical Cancer.
Zhou J; Zhang Y; Zou X; Kuai L; Wang L; Wang J; Shen F; Hu J; Zhang X; Huang Y; Chen Y
Hum Gene Ther; 2020 Mar; 31(5-6):385-395. PubMed ID: 31870179
[TBL] [Abstract][Full Text] [Related]
2. TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/β-catenin signaling pathway and promoting the epithelial mesenchymal transition.
Liu SL; Lin HX; Lin CY; Sun XQ; Ye LP; Qiu F; Wen W; Hua X; Wu XQ; Li J; Song LB; Guo L
Cancer Lett; 2017 Aug; 402():117-130. PubMed ID: 28583847
[TBL] [Abstract][Full Text] [Related]
3. Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.
Wang Z; Li F; He S; Zhao L; Wang F
Gene; 2022 Jan; 809():146003. PubMed ID: 34648915
[TBL] [Abstract][Full Text] [Related]
4. Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
Li R; Liu GZ; Luo SY; Chen R; Zhang JX
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4533-41. PubMed ID: 26698249
[TBL] [Abstract][Full Text] [Related]
5. Silencing GOLPH3 gene expression reverses resistance to cisplatin in HT29 colon cancer cells via multiple signaling pathways.
Zhou ZP; Wang LP; Hong ZS; Qiu CZ; Wang MZ; Chen ZX; Tang LF; Yu WS; Wang CX
Int J Oncol; 2018 Sep; 53(3):1183-1192. PubMed ID: 30015866
[TBL] [Abstract][Full Text] [Related]
6. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity.
Feng LL; Shen FR; Zhou JH; Chen YG
Gene; 2019 May; 696():105-112. PubMed ID: 30738960
[TBL] [Abstract][Full Text] [Related]
7. Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells.
Mehta H; Ambele MA; Mokgautsi N; Moela P
Cells; 2024 Apr; 13(8):. PubMed ID: 38667315
[TBL] [Abstract][Full Text] [Related]
8. The synergistic therapeutic effect of cisplatin with Human papillomavirus E6/E7 short interfering RNA on cervical cancer cell lines in vitro and in vivo.
Jung HS; Erkin OC; Kwon MJ; Kim SH; Jung JI; Oh YK; Her SW; Ju W; Choi YL; Song SY; Kim JK; Kim YD; Shim GY; Shin YK
Int J Cancer; 2012 Apr; 130(8):1925-36. PubMed ID: 21630254
[TBL] [Abstract][Full Text] [Related]
9. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
Chen X; Xiong D; Ye L; Yang H; Mei S; Wu J; Chen S; Mi R
Cancer Chemother Pharmacol; 2019 Apr; 83(4):603-613. PubMed ID: 30627777
[TBL] [Abstract][Full Text] [Related]
10. ERK-mediated TIMELESS expression suppresses G2/M arrest in colon cancer cells.
Neilsen BK; Frodyma DE; McCall JL; Fisher KW; Lewis RE
PLoS One; 2019; 14(1):e0209224. PubMed ID: 30629587
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells.
Zhang X; Pan C; Zhou L; Cai Z; Zhao S; Yu D
BMC Cancer; 2016 Dec; 16(1):949. PubMed ID: 27986075
[TBL] [Abstract][Full Text] [Related]
12. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3.
Jing Z; Heng W; Xia L; Ning W; Yafei Q; Yao Z; Shulan Z
Cancer Biol Ther; 2015; 16(4):541-8. PubMed ID: 25719555
[TBL] [Abstract][Full Text] [Related]
14. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
Zhang WY; Liu YJ; He Y; Chen P
J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
Zheng H; Wang JJ; Yang XR; Yu YL
World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline Induces Apoptosis and Inhibits Proliferation and Invasion of Human Cervical Carcinoma Stem Cells.
Yang B; Lu Y; Zhang A; Zhou A; Zhang L; Zhang L; Gao L; Zang Y; Tang X; Sun L
PLoS One; 2015; 10(6):e0129138. PubMed ID: 26111245
[TBL] [Abstract][Full Text] [Related]
18. Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer.
Wang T; Liu Z; Shi F; Wang J
Mol Cell Biochem; 2016 Feb; 413(1-2):179-87. PubMed ID: 26820938
[TBL] [Abstract][Full Text] [Related]
19. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
20. Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma.
Zhang W; He W; Shi Y; Zhao J; Liu S; Zhang F; Yang J; Xie C; Zhang Y
Int J Oncol; 2017 Jan; 50(1):173-184. PubMed ID: 27909716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
